HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients by L. Valenti et al.
HFE Mutations Modulate the Effect of Iron on Serum
Hepcidin-25 in Chronic Hemodialysis Patients
Luca Valenti,* Domenico Girelli,† Giovanni Francesco Valenti,‡ Annalisa Castagna,†
Giovanna Como,‡ Natascia Campostrini,† Raffaela Rametta,* Paola Dongiovanni,*
Piergiorgio Messa,‡ and Silvia Fargion*
*Center for Metabolic and Liver Diseases, Department of Internal Medicine, Universita` degli Studi di Milano,
Fondazione Ospedale Maggiore Policlinico MaRE IRCCS, Milano, Italy; †Department of Clinical and Experimental
Medicine, University of Verona, Policlinico GB Rossi, Verona, Italy; and ‡Department of Nephrology, Fondazione
Ospedale Maggiore Policlinico MaRE IRCCS, Milano, Italy
Background and objectives: Increased serum hepcidin has been reported in patients receiving chronic hemodialysis, and
hypothesized to contribute to the alterations of iron metabolism of end-stage renal disease. However, no quantitative
assessment is available to date; the clinical determinants are still under definition; and the role of genetic factors, namely HFE
mutations, has not yet been evaluated. The aim of this study was to quantitatively assess serum hepcidin-25 in hemodialysis
patients versus controls, and analyze the relationship between hepcidin, iron indices, HFE genotype, and erythropoietic
parameters.
Design, setting, participants & measurements: Sixty-five hemodialysis patients and 57 healthy controls were considered.
Hepcidin-25 was evaluated by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, HFE genotype
by restriction analysis.
Results: Serum hepcidin-25 was higher in hemodialysis patients compared with controls. In patients, hepcidin-25 correlated
positively with ferritin and C reactive protein, and negatively with serum iron after adjustment for confounders. Hepcidin/
ferritin ratio was lower in patients with (n  25) than in those without (n  40) HFE mutations. At multivariate analysis,
hepcidin-25 was independently associated with ferritin and HFE status. In a subgroup of 22 “stable” patients, i.e., with Hb
levels on target, normal CRP levels, and absence of complications for at least 1 yr, hepcidin-25 was negatively correlated with
Hb levels independently of confounders.
Conclusions: Serum hepcidin-25 is increased in hemodialysis patients, regulated by iron stores and inflammation, and
relatively reduced in subjects carrying frequent HFE mutations. Hepcidin-25 may contribute to the pathogenesis of anemia by
decreasing iron availability.
Clin J Am Soc Nephrol 4: 1331–1337, 2009. doi: 10.2215/CJN.01370209
I ncreased serum levels of hepcidin, the novel iron hormoneinhibiting iron absorption from enterocytes and iron recy-cling from macrophages, have recently been reported in
patients with end-stage renal disease (ESRD), and hypothesized
to contribute to the alterations of iron metabolism and anemia
of ESRD (1–5).
Anemia related to renal failure, blood losses, and chronic
inflammation is an almost universal finding in patients with
ESRD receiving chronic hemodialysis treatment (CHD), and is
associated with increased mortality (6,7). Treatment is based on
erythropoiesis stimulating agents (ESAs) in association with i.v.
iron formulations (8). Functional iron deficiency is a common
finding, determining the need for high doses of ESAs and iron,
both associated with adverse events. High doses of ESAs in-
crease the risk of mortality due to cardiovascular events related
to hypertension and hypercoagulability (9–11), whereas excess
iron promotes vascular damage by inducing oxidative stress
and heightens the risk of infections (12–16). The mechanism
proposed to explain refractoriness to i.v. iron is related to the
inhibition of erythropoiesis and iron recycling from macro-
phages by inflammation (17).
The alteration of iron metabolism of CHD is characterized by
decreased transferrin saturation, resulting in reduced iron
availability for erythropoiesis, and is supposed to be related to
chronic inflammation and/or blood losses (18). Hyperferritine-
mia is also frequently observed, and although in the most
severe cases excess iron administration is believed to play a
role, in the majority of cases it is thought to reflect the malnu-
trition inflammation cachexia syndrome (19). It has been shown
that inflammation and oxidative stress induce iron retention in
monocytes/macrophages and the transcription of ferritin, a
protein with anti-oxidant activity (20,21). However, recent data
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highlight that ferritin levels reflect also iron stores in CHD
patients. Indeed, in these subjects ferritin correlated positively
with transferrin saturation, with the presence of common mu-
tations of the HFE gene of hereditary hemochromatosis (12),
and with bone marrow iron stores (22).
HFE mutations, the most common cause of iron overload in
Caucasians (23), disrupt the physiologic regulation of hepcidin
by hepatic iron stores. Hepcidin inhibits intestinal iron absorp-
tion and iron recycling from monocytes by binding and inacti-
vating the iron exporter Ferroportin-1 (Fp-1) (24). Furthermore,
hepcidin is an acute phase reactant induced by inflammation
and is downregulated by anemia, hypoxia and erythropoietin
(5,25,26).
Until very recently, no reliable and practical assay to measure
serum hepcidin was available. Thus, the effect of ESRD and
CHD on the regulation of hepcidin, which is physiologically
excreted with urine, and the influence of hepcidin on the reg-
ulation of iron metabolism in patients with ESRD are still under
definition. In previous studies, elevated levels of serum pro-
hepcidin, an immature form of hepcidin measured by ELISA,
were found in patients with ESRD (2). However, pro-hepcidin
levels have not been found to correlate with mature biologically
active hepcidin and with iron stores (1,27).
An increase in serum hepcidin-25, the biologically active
form of the hormone, measured by a semiquantitative ap-
proach, has recently been reported in studies including small
samples of CHD patients. Interestingly, hepcidin levels were
correlated with ferritin in these subjects (1,4). Theoretically,
increased hepcidin levels may reduce intestinal iron absorption
and iron recycling from monocytes (24), decreasing serum iron
available for the erythropoiesis (28) and the therapeutic effect of
ESAs and i.v. iron, as commonly observed in CHD patients (3).
Supporting this hypothesis, we recently reported that frequent
mutations in the HFE gene, which decrease hepcidin response
to iron stores (29,30), are associated with increased sensitivity to
ESAs and iron in CHD patients, and may be associated with a
better clinical outcome (31). However, in a study considering a
series of 24 patients, hepcidin-25 was not significantly associ-
ated with r-HuEpo responsiveness (1).
The aim of this study was to evaluate serum hepcidin-25
levels by a quantitative approach (27) in CHD patients treated
with a standardized protocol according to current guidelines
and in controls, and to evaluate in CHD the possible relation-
ship of hepcidin with markers of iron status, the HFE genotype
and erythropoietic parameters.
Materials and Methods
Sixty-five of 110 prevalent CHD patients treated at the Fondazione
Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena IRCCS of
Milan, with available serum and DNA samples, were included. Exclu-
sion criteria were active major infectious diseases (pneumonia, sepsis),
neoplasia, congestive heart failure (NYHA stage III and IV), unstable
ischemic heart disease, hepatic failure, and the -thalassemic trait. Part
of this series has previously been described elsewhere in detail (12,31).
Twenty-two of these patients could be considered “stable”, i.e., had
Hb levels on target (between 10.5 and 12 g/dl during the last 12 mo
before enrollment, without changes in the dose of recombinant human
erythropoietin [r-HuEpo] and iron), normal CRP levels (4 mg/dl) and
absence of complications (clinically detectable bleeding and hospital-
ization) for at least one year before enrollment. These stable patients
were characterized by younger age (P  0.02), higher ferritin levels
(P  0.001) and lower CRP levels (P  0.0002), compared with the
others.
Patients were dialyzed with synthetic biocompatible membranes and
bicarbonate dialysate, and given i.v. r-HuEpo (Eprex®) t.i.w. at a dose
aimed to maintain hemoglobin (Hb) between 10.5 and 12 g/dl. Iron was
administered i.v. as Fe3-gluconate (Ferlixit®) when transferrin satu-
ration was 30% or ferritin 200 ng/ml, and suspended when ferritin
was above 500 ng/ml, as suggested by guidelines (8). Iron infusion was
started b.i.w. and titrated according to requirements. Clinicians were
unaware of HFE genotypes and hepcidin dosage of the patients
throughout the duration of the study.
Blood samples for complete blood count, iron parameters (tested by
standard methods) and hepcidin-25 were collected before hemodialysis
at standardized times after the last administration of therapies, poten-
tially altering iron status and hepcidin release: 1 wk after the last dose
of i.v. iron, and 3 d after the last dose of r-HuEpo in all patients. At the
time of evaluation, all patients were receiving a defined amount of iron
and r-HuEpo to support erythropoiesis.
HFE genotype was determined by restriction analysis (32).
Fifty-seven gender-matched controls were enrolled among healthy
volunteers participating in a phase II trial at the Centre for Clinical
Research of the Azienda Ospedaliera-Universitaria di Verona, as de-
scribed previously in detail elsewhere (33). Briefly, at enrollment they
completed a questionnaire with specific items relevant to iron metab-
olism (i.e., any history of blood donations, previous pregnancy, men-
strual losses, etc.) and were evaluated by laboratory studies including
complete blood count, serum iron, transferrin saturation, ferritin, in-
flammatory markers (including CRP), liver function tests and creati-
nine. To be considered as appropriate “normal controls” for the serum
hepcidin assay, all these parameters were required to be normal.
Clinical features of subjects included in the study are shown in
Table 1.
Each patient gave written informed consent. The study was con-
ducted according to the principles contained in the Declaration of
Helsinki. The protocol was approved by the Institutional Review
Boards of the Ospedale Maggiore Policlinico Mangiagalli Regina Elena
Fondazione IRCSS of Milano, and of the Azienda Ospedaliera-Univer-
sitaria of Verona.
Serum Hepcidin Assay
We used a protocol based on PBSCIIc mass spectrometer and copper-
loaded immobilized metal-affinity capture ProteinChip arrays
(IMAC30-Cu2). Five l of serum were applied to an IMAC30-Cu2
surface that binds hepcidin based on its affinity for Cu2 ions. The
binding surface was equilibrated and washed with appropriate buffers
according to the manufacturer’s instructions (Bio-Rad, Hercules, CA).
Subsequent work-up, SELDI-TOF MS instrumental settings, read out,
and data analysis are described elsewhere (33), with the addition that
protein chip handling was performed in a nitrogen atmosphere to
prevent methionine oxidation (27). A synthetic hepcidin analogue (hep-
cidin-24, Peptides International, Louisville, KY) was used as an internal
standard (27). Concentrations of serum hepcidin-25 were expressed as
nM. Hepcidin-25 concentration of 0.5 nM (half the lower detectable
concentration in these series) was arbitrarily assigned to samples with
undetectable serum hepcidin-25. The intra- and interassay coefficient of
variations of this method ranged from 6.1 to 7.3 percent, and from 5.7
to 11.7 (mean 7.7) percent, respectively (29).
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Statistical Analysis
Since the C282Y and H63D are both loss-of-function HFE mutations,
and are not associated with iron overload in the general population
(23), but are both associated with more favorable erythropoietic param-
eters in patients with CHD (31), we grouped together, for the primary
analysis, subjects positive for either one of the two mutations. We also
present results for the effect of specific HFE genotypes.
Results are expressed as means  SD for normally distributed vari-
ables and as median {interquartile range} for non-normally distributed
variables, including serum hepcidin-25 levels, ferritin and CRP. Quan-
titative variables were correlated by Spearman’s rho test, and hepci-
din-25 levels were compared between groups by the Wilcoxon test. To
evaluate the effect of HFE genotype on the hepcidin-25 response to iron
stores, we also evaluated the hepcidin-25/ferritin ratio, an established
marker of adequacy of hepcidin response to iron stores (33,34). Inde-
pendent predictors of serum hepcidin-25, Hb levels, and serum iron
levels were evaluated by multivariate analysis (generalized linear
model) including variables identified at univariate analysis. Results
were considered significant when p was 0.05 (two-tailed). Analyses
were carried out with the JMP 6.0 statistical analysis software (SAS
Institute Inc, Cary, NC).
Results
Hepcidin-25 was significantly higher in patients compared
with controls (10.63 {2.67 to 23.66} versus 4.62 {3.01 to 7.02} nM,
P  0.0021) (Figure 1).
Correlations of hepcidin-25 with clinical variables including
iron indices, inflammation and erythropoietic parameters in
CHD patients are shown in Table 2. In the whole CHD popu-
lation, hepcidin-25 was not correlated with demographic and
anthropometric features, the duration of dialysis and measures
of dialysis adequacy. Hepcidin-25 was significantly correlated
with serum ferritin (Spearman’s rho  0.46; P  0.0001,
Figure 2), but not with transferrin saturation, the dose of iron
and r-HuEpo. We observed a trend for a negative correlation
between hepcidin-25 and serum iron (rho  0.20; P  0.1).
Hepcidin-25 was also correlated with CRP levels (rho  0.27;
P  0.029, Figure 2).
At multivariate analysis considering hepcidin-25, ferritin,
CRP, monthly iron dosage and the presence of HFE mutations,
serum iron was independently associated with hepcidin-25
Table 1. Clinical features of 57 healthy controls and 65 Italian CHD patients
Controls
n  57
Overall Series of Patients
n  65
Stable Patients
n  22
Age years 35 15 65.5 12 61.9 9
Sex F 21 (36.8) 26 (40) 9 (40.9)
Dialysis duration months - 35.5 {19-87} 56 {24-112}
Hypertension - 22 (34) 10 (45)
Diabetes 0 8 (12.3) 1 (4.5)
Smoke - 19 (29) 7 (32)
Albumin g/dl - 3.7 0.5 3.6  0.5
PTH - 360 {137-780} 365 {115-611}
Hb g/dl 14.4 1.2 10.8 1.1 10.9  0.7
r-HuEpo IU/Kg/wk 0 90.9 {36-137} 87.3 {42-142}
Iron mg/mo 0 67.5 {10-127} 86 {51-136}
Ferritin ng/ml 90 {47-149} 236 {128-410} 369 {244-528}
Transferrin saturation % 28.9 9 26.3 10 27.8  8
CRP mg/dl 0.8 {0.8-1.4} 2.3 {0.8-4.3} 0.85 {0.4-2.3}
HFE genotype
wt/wt - 40 (61.5) 11 (50)
H63D/wt - 18 (27.7) 9 (40.9)
C282Y/wt - 4 (6.2) 0
H63D/H63D - 3 (4.6) 2 (9.1)
( ), % values; { }, interquartile range; wt, wild-type.
Figure 1. Hepcidin-25 levels in 57 healthy controls and 65 CHD
patients (P  0.0021). Outlier box plots represent interquartile
ranges, whereas lines that cross the boxes indicate the median
value. The whiskers extend to the 1.5x interquartile range dis-
tances.
Clin J Am Soc Nephrol 4: 1331–1337, 2009 HFE Mutations and Hepcidin in Hemodialysis 1333
(parameter estimate 0.81, P  0.014), monthly iron dose (es-
timate 0.08, P  0.04) and the presence of HFE mutations
(estimate  11.32, P  0.017).
The effect of HFE genotype on hepcidin-25 levels and on the
hepcidin-25/ferritin ratio (nM/ng/ml) is shown in Figure 3.
Hepcidin-25/ferritin ratio was significantly lower in patients
positive (n  25, 38.5%) compared with those who were nega-
tive (n  40, 61.5%) for HFE mutations (0.02 {0.010 to 0.062}
versus 0.05 {0.018 to 0.095}; P  0.045).
At multivariate analysis considering as independent vari-
ables ferritin, CRP levels, and the presence of HFE mutations,
hepcidin-25 levels were independently associated with ferritin
(parameter estimate  0.03, P  0.0001), and the absence of
HFE mutations (estimate  4.05, P  0.0184), but not signifi-
cantly associated with CRP (estimate  0.56, P  0.103).
In a subgroup of 22 “stable” patients, as defined in the
Methods and Materials section (whose clinical features are
shown in Table 1), hepcidin-25 was correlated with ferritin
(rho  0.42; P  0.05) and negatively correlated with Hb
levels (rho  0.51; P  0.015) (Table 2). We also observed a
trend for a negative correlation with serum iron (rho  0.38;
P 0.08). In this subgroup, at multivariate analysis considering
hepcidin-25, sex, transferrin saturation %, ferritin, r-HuEpo
dose, iron dose, and CRP, Hb was independently associated
with hepcidin-25 (estimate –0.062; P  0.0011) and CRP (esti-
mate –0.179; P  0.017).
Discussion
To the best of our knowledge, this is the largest series of CHD
patients analyzed for serum hepcidin levels, and the first one in
which a quantitative assay was used. We also investigated the
effect of common HFE gene mutations on hepcidin-25, and
provide data supporting the possible role of hepcidin-25 in the
pathophysiology of the alterations of iron metabolism and ane-
mia.
Our data clearly confirm and extend previous reports based
on a semiquantitative assay in smaller series, suggesting sub-
stantial hepcidin-25 upregulation in CHD patients compared
with controls (4,5), and preserved regulation of hepcidin-25 by
iron stores and inflammation in this setting (1,4). They also
provide evidence of a modulating effect of HFE mutations on
hepcidin-25 regulation by iron stores.
First, we showed that hepcidin-25 levels are higher in pa-
tients receiving CHD than in healthy controls. Notably, while
the groups studied were matched for gender, which is a major
determinant of serum hepcidin levels (27,35), CHD patients
were significantly older than controls. However, this is unlikely
to represent a substantial bias, since previous studies did not
Table 2. Correlation between hepcidin-25 levels and clinical features in 65 Italian patients receiving CHD
Overall Series
(n  65)
Stable Patients
(n  22)
rho p rho p
Age 0.01 0.91 -0.01 0.97
Dialysis duration 0.03 0.82 -0.07 0.76
Hemoglobin g/dl 0.05 0.67 -0.51 0.015
r-HuEpo IU/Kg/wk 0.002 0.99 0.25 0.26
Serum iron g/dl -0.274 0.15 -0.38 0.08
Transferrin saturation % -0.003 0.99 -0.28 0.21
Ferritin ng/ml 0.46 0.0001 0.42 0.05
Iron mg/month -0.159 0.35 0.12 0.59
CRP mg/dl 0.27 0.029 0.1 0.66
Figure 2. Correlation between hepcidin-25, ferritin and CRP in 65 Italian CHD patients (P  0.0001 and P  0.029, respectively,
at Spearman’s test).
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show a consistent increase in hepcidin levels with age in the
general population (35). These data suggest that ESRD itself
plays a role in hepcidin-25 accumulation in this setting.
Whether different dialytic techniques may affect the rate of
hepcidin-25 clearance in CHD, and the consequences on iron
metabolism and erythropoiesis, must be ascertained by future
studies.
Also, we showed preserved regulation of hepcidin-25 levels
by iron stores, as demonstrated by the very strong correlation
with serum ferritin, and modulation by inflammation, as de-
tected by CRP levels. Again, these data match closely those
previously obtained, showing a correlation of hepcidin-25 with
ferritin and IL-6, but not CRP, in CHD, and, anecdotally, an
increase in hepcidin-25 after i.v. iron administration (1,4).
Moreover, for the first time we were able to demonstrate a
negative correlation between hepcidin-25 and serum iron.
These results imply that in CHD, excessive iron administration
may paradoxically hamper iron utilization for erythropoiesis
by trapping iron in phagocytes, because of excessive hepci-
din-25 induction favored by chronic inflammation, and that the
effect of inflammation on altered iron metabolism and erythro-
poiesis may be mediated by increased hepcidin levels. They
also suggest that pharmacologic downregulation of hepcidin
(36) may be beneficial in CHD.
This hypothesis is supported by recent data by our group
indicating that frequent HFE mutations, affecting about 30% of
Caucasians and believed to cause a relative deficit in hepcidin
release (30,34), are associated with higher iron availability,
more efficient erythropoiesis, and possibly a better prognosis
(31). In the general population, the C282Y HFE mutation is
detected in about 3 to 10%, whereas the H63D in about 22 to
28% of subjects. However, only the C282Y /, C282Y /
H63D / and H63D / HFE genotypes have been associ-
ated with increased susceptibility to develop iron overload and
clinical manifestations of hemochromatosis (23). In subjects
without ESRD, chronic inflammation and liver disease, simple
heterozygosity for the H63D or the C282Y HFE mutations was
not found to be associated with either iron overload (23) or
reduced hepcidin release (33), and previous data obtained in a
very limited number of CHD patients did not support an
influence of increased hepcidin on r-HuEpo requirement (1).
To clarify this important issue, we analyzed the effect of HFE
mutations on hepcidin-25 levels and found that the presence of
either the H63D or the C282Y mutations was associated with
reduced induction of hepcidin-25 by iron stores, and was an
independent predictor of hepcidin-25 levels at multivariate
analysis. These results clearly suggest that in CHD, simple
heterozygosity for HFE mutations alters iron metabolism by
decreasing hepcidin levels. The subtle effect of these molecular
variants is likely magnified in CHD patients by the environ-
mental pressure determined by chronic inflammation and ex-
posure to high amounts of iron and ESAs.
Furthermore, we found that in a subgroup of patients with
stable disease, selected to avoid the confounding effect of the
frequent presence of acute inflammation, blood losses, cancer
and recent variation in the dosage of therapy, hepcidin-25
negatively correlated with Hb levels and there was a trend
toward a negative correlation with lower serum iron.
Since anemia and hyposideremia should rather decrease hep-
cidin levels, these findings suggest that hepcidin-25 plays a
causal role in determining anemia by reducing iron availability
to the erythron. To our knowledge, this is the first evidence
supporting the theory that hepcidin is involved in the patho-
genesis of the anemia of CHD.
However, results should be confirmed in larger series includ-
ing patients from different centers and ethnic background, with
prospective evaluation of the effect of serum hepcidin levels.
Given the possible relevance of HFE genotype for determin-
ing the prognosis and guiding therapy in patients receiving
CHD, and the theoretical possibility to improve anemia man-
agement by pharmacologic modulation of hepcidin release,
additional studies including larger series of patients analyzing
the effect of HFE genotype on iron metabolism, erythropoiesis
and clinical outcomes are required.
In conclusion, serum hepcidin-25 is increased in CHD, reg-
ulated by iron stores and inflammation, and relatively reduced
Figure 3. Hepcidin-25 quantitative levels (nM) and hepcidin-25/ferritin ratio (nM/ng/ml) in 65 CHD patients subdivided
according to HFE genotype. Outlier box plots represent interquartile ranges, whereas lines that cross the boxes indicate the median
value. The whiskers extend to the 1.5x interquartile range distances.
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in subjects carrying frequent HFE mutations. Since increased
hepcidin-25 may contribute to the pathogenesis of anemia by
decreasing iron availability, the mechanisms underlying hepci-
din-25 accumulation in ESRD and the therapeutic implications
of these findings warrant further investigations.
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